Clinical Trials

June 27, 2017 By; KCB Admin

Clinical Trial; KCB case 062917a

June 29, 2017 - By: KCB Admin
Case 062917a  I.V. CR845
Breakthrough Therapy Designation for I.V. CR845 for UP CKD WEDNESDAY, JUNE 28, 2017

Cara Therapeutics, a bio pharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, announced that the FDA has granted Breakthrough Therapy designation to I.V. CR845 for the treatment of moderate-to-severe uremic pruritus (UP) in chronic kidney disease (CKD) patients undergoing hemodialysis.

“The FDA’s decision to grant Breakthrough Therapy designation is recognition of both the significant unmet medical need among CKD patients with UP and the potential of I.V. CR845 to address it,” said Derek Chalmers, Ph.D., D.Sc., president and chief executive officer of Cara Therapeutics. “We have already initiated our phase III program and look forward to working closely with the FDA to bring this potential new treatment option to hemodialysis patients as quickly as possible.”

MD Anderson; Clinical Trials

June 30, 2017  By: KCB Admin
As part of our mission to eliminate cancer, MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers. Look through our database to find studies for which you may be eligible. 1515 Holcombe Blvd. Houston, Texas 77030